EP2628799A3 - Modulation ARNi de RSV et utilisations thérapeutiques associées - Google Patents

Modulation ARNi de RSV et utilisations thérapeutiques associées Download PDF

Info

Publication number
EP2628799A3
EP2628799A3 EP13152226.0A EP13152226A EP2628799A3 EP 2628799 A3 EP2628799 A3 EP 2628799A3 EP 13152226 A EP13152226 A EP 13152226A EP 2628799 A3 EP2628799 A3 EP 2628799A3
Authority
EP
European Patent Office
Prior art keywords
rsv
gene
therapeutic uses
subject
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13152226.0A
Other languages
German (de)
English (en)
Other versions
EP2628799A2 (fr
Inventor
Rachel Meyers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alnylam Pharmaceuticals Inc
Original Assignee
Alnylam Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnylam Pharmaceuticals Inc filed Critical Alnylam Pharmaceuticals Inc
Publication of EP2628799A2 publication Critical patent/EP2628799A2/fr
Publication of EP2628799A3 publication Critical patent/EP2628799A3/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/06—Sprayers or atomisers specially adapted for therapeutic purposes of the injector type
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP13152226.0A 2005-01-07 2006-01-06 Modulation ARNi de RSV et utilisations thérapeutiques associées Withdrawn EP2628799A3 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US64236405P 2005-01-07 2005-01-07
US65982805P 2005-03-09 2005-03-09
EP10007180A EP2230304B1 (fr) 2005-01-07 2006-01-06 Modulation de RSV par ARNi et ses applications thérapeutiques
EP06717600A EP1833490A4 (fr) 2005-01-07 2006-01-06 Modulation d'arn interferent du virus respiratoire syncytial et utilisations therapeutiques de cette modulation
EP12161280.8A EP2487243A3 (fr) 2005-01-07 2006-01-06 Modulation de l'ARNi du VRS et utilisations thérapeutiques correspondantes

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
EP06717600.8 Division 2006-01-06
EP10007180.2 Division 2010-07-12
EP12161280.8 Division 2012-03-26

Publications (2)

Publication Number Publication Date
EP2628799A2 EP2628799A2 (fr) 2013-08-21
EP2628799A3 true EP2628799A3 (fr) 2013-08-28

Family

ID=36648197

Family Applications (4)

Application Number Title Priority Date Filing Date
EP06717600A Withdrawn EP1833490A4 (fr) 2005-01-07 2006-01-06 Modulation d'arn interferent du virus respiratoire syncytial et utilisations therapeutiques de cette modulation
EP13152226.0A Withdrawn EP2628799A3 (fr) 2005-01-07 2006-01-06 Modulation ARNi de RSV et utilisations thérapeutiques associées
EP10007180A Not-in-force EP2230304B1 (fr) 2005-01-07 2006-01-06 Modulation de RSV par ARNi et ses applications thérapeutiques
EP12161280.8A Withdrawn EP2487243A3 (fr) 2005-01-07 2006-01-06 Modulation de l'ARNi du VRS et utilisations thérapeutiques correspondantes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP06717600A Withdrawn EP1833490A4 (fr) 2005-01-07 2006-01-06 Modulation d'arn interferent du virus respiratoire syncytial et utilisations therapeutiques de cette modulation

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP10007180A Not-in-force EP2230304B1 (fr) 2005-01-07 2006-01-06 Modulation de RSV par ARNi et ses applications thérapeutiques
EP12161280.8A Withdrawn EP2487243A3 (fr) 2005-01-07 2006-01-06 Modulation de l'ARNi du VRS et utilisations thérapeutiques correspondantes

Country Status (14)

Country Link
US (8) US7507809B2 (fr)
EP (4) EP1833490A4 (fr)
JP (3) JP5081630B2 (fr)
KR (1) KR101169668B1 (fr)
CN (2) CN102600480B (fr)
AT (1) ATE551421T1 (fr)
AU (2) AU2006203934B2 (fr)
CA (1) CA2594334A1 (fr)
DK (1) DK2230304T3 (fr)
EA (3) EA012573B1 (fr)
ES (1) ES2385811T3 (fr)
IL (2) IL184162A (fr)
NZ (1) NZ556097A (fr)
WO (1) WO2006074346A2 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
DE10100586C1 (de) * 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
CZ302719B6 (cs) 2000-12-01 2011-09-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7767802B2 (en) * 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
US7592322B2 (en) * 2004-10-22 2009-09-22 Alnylam Pharmaceuticals, Inc. RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
NZ556097A (en) * 2005-01-07 2009-12-24 Alnylam Pharmaceuticals Inc Rnai modulation of RSV and therapeutic uses thereof
WO2006094014A2 (fr) 2005-02-28 2006-09-08 The Regents Of The University Of California Methodes pour diagnostiquer et pour traiter un cancer endometrique
US8648052B2 (en) * 2005-04-15 2014-02-11 The Regents Of The University Of California Prevention of chlamydia infection using SIRNA
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
WO2006113526A2 (fr) 2005-04-15 2006-10-26 The Regents Of The University Of California Procede pour prevenir une infection a chlamydia au moyen d'un anticorps protecteur
ES2426684T3 (es) 2007-03-23 2013-10-24 To-Bbb Holding B.V. Conjugados para el suministro dirigido de fármacos a través de la barrera hematoencefálica
WO2008132723A2 (fr) * 2007-04-26 2008-11-06 Quark Pharmaceuticals, Inc. Délivrance thérapeutique de molécules d'acide nucléique inhibitrices dans le système respiratoire
EP2316943B1 (fr) 2007-07-05 2013-06-19 Novartis AG ARNDB pour le traitement de l'infection virale
WO2011063161A2 (fr) 2009-11-20 2011-05-26 The Regents Of The University Of California Protéine 2 de membrane épithéliale (emp2) et vitréorétinopathie proliférative (pvr)
CA2702094C (fr) * 2007-10-10 2018-05-01 Parion Sciences, Inc. Administration d'osmolytes par canule nasale
WO2009055445A2 (fr) * 2007-10-22 2009-04-30 Sirna Therapeutics, Inc. Inhibition induite par l'interférence arn de l'expression du virus syncytial respiratoire (vsr), au moyen d'un acide nucléique interférant court (sina)
US20090238772A1 (en) * 2007-12-13 2009-09-24 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of rsv infection
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
EP2350277A1 (fr) * 2008-10-23 2011-08-03 Alnylam Pharmaceuticals, Inc. Procédés et compositions pour la prévention ou le traitement d'une infection par le rsv à l'aide de molécules d'arn en duplex modifiées
WO2010141511A2 (fr) * 2009-06-01 2010-12-09 Halo-Bio Rnai Therapeutics, Inc. Polynucléotides pour interférence arn multivalente, compositions et procédés pour les utiliser
US20120220649A1 (en) * 2009-10-30 2012-08-30 Daiichi Sankyo Company, Limited Modified double-stranded polynucleotide
JP2013528665A (ja) 2010-03-26 2013-07-11 メルサナ セラピューティックス， インコーポレイテッド ポリヌクレオチドの送達のための修飾ポリマー、その製造方法、およびその使用方法
EP3372684B1 (fr) * 2010-08-24 2020-10-07 Sirna Therapeutics, Inc. Agents d'arni à un seul brin contenant un espaceur interne d'acide non nucléique
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
EP2717855A4 (fr) 2011-06-07 2014-11-12 Parion Sciences Inc Procédés de traitement
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
KR102109223B1 (ko) 2012-05-29 2020-05-11 패리온 사이언스 인코퍼레이티드 안구 건조 및 다른 점막 질환의 치료를 위한 나트륨 채널 차단제 활성을 보유하는 덴드리머 유사 아미노 아미드
CA2896686A1 (fr) 2012-12-17 2014-06-26 Parion Sciences, Inc. Composes 3,5-diamino -6-chloro-n-(n- (4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide
ES2619954T3 (es) 2012-12-17 2017-06-27 Parion Sciences, Inc. Derivados de cloropiracinocarboxamida útiles para el tratamiento de enfermedades favorecidas por una hidratación mucosa insuficiente
BR112015014178A2 (pt) 2012-12-17 2017-07-11 Parion Sciences Inc compostos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil)carbamimidoil) pirazina-2- carboxamida
KR20150137350A (ko) * 2014-05-29 2015-12-09 삼성전자주식회사 화상형성장치 및 화상형성장치의 스캔 방법
AU2016312530A1 (en) 2015-08-24 2018-03-01 Halo-Bio Rnai Therapeutics, Inc. Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
CN105693557A (zh) * 2016-01-04 2016-06-22 湖北卓熙氟化股份有限公司 一种氟化氢尿素及其制备方法
JP2018012236A (ja) * 2016-07-20 2018-01-25 株式会社東芝 印刷システム
CN108689886B (zh) * 2018-06-22 2021-06-15 湖北卓熙氟化股份有限公司 一种氟化氢尿素的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995023225A2 (fr) * 1994-02-23 1995-08-31 Ribozyme Pharmaceuticals, Inc. Procede et reactif inhibiteur de l'expression de genes concernant une affection
WO2004090108A2 (fr) * 2003-04-03 2004-10-21 Alnylam Pharmaceuticals Conjugues d'arni

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
HU205839B (en) * 1987-11-18 1992-07-28 Chinoin Gyogyszer Es Vegyeszet Synergetic artropodicide composition containining pirethroides and phosphate-esters as active components
US5693532A (en) * 1994-11-04 1997-12-02 Ribozyme Pharmaceuticals, Inc. Respiratory syncytial virus ribozymes
US20020032160A1 (en) * 1995-02-24 2002-03-14 Nyce Jonathan W. Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
WO1997014792A2 (fr) * 1995-10-17 1997-04-24 Hybridon, Inc. Oligonucleotides presentant une activite contre le virus respiratoire syncytial
US6214805B1 (en) 1996-02-15 2001-04-10 The United States Of America As Represented By The Department Of Health And Human Services RNase L activators and antisense oligonucleotides effective to treat RSV infections
CA2246503A1 (fr) * 1996-02-15 1997-08-21 National Institutes Of Health Activateurs de rnase l et oligonucleotides antisens efficaces dans le traitement des infections a rsv
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
AU4425397A (en) 1996-09-18 1998-04-14 Vanderbilt University Antisense gene therapy for rna viruses
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
FR2798857B1 (fr) * 1999-09-23 2003-06-06 Pf Medicament Utilisation d'une proteine de membrane ompa d'enterobacterie associee a un peptide immunogene du vrs pour la preparation de vaccins administrables par voie nasale
US20070026394A1 (en) * 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
CZ302719B6 (cs) * 2000-12-01 2011-09-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití
US20030170891A1 (en) * 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20060287267A1 (en) * 2001-05-18 2006-12-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
US20030148928A1 (en) 2001-07-20 2003-08-07 Leonid Beigelman Enzymatic nucleic acid peptide conjugates
US6881835B2 (en) 2002-01-04 2005-04-19 Dr. Chip Biotechnology Inc. Detection of respiratory viruses
WO2003062258A1 (fr) 2002-01-22 2003-07-31 The Cleveland Clinic Foundation Complexes antisens-activateur d'arnase l
US20030203868A1 (en) * 2002-02-06 2003-10-30 Bushman Frederic D. Inhibition of pathogen replication by RNA interference
AU2003299531A1 (en) 2002-08-05 2004-06-07 University Of Massachusetts Compounds for modulating rna interference
US7923547B2 (en) * 2002-09-05 2011-04-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
WO2004028471A2 (fr) * 2002-09-28 2004-04-08 Massachusetts Institute Of Technology Therapeutique antigrippale
US20040242518A1 (en) 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
ATE517992T1 (de) * 2002-11-14 2011-08-15 Dharmacon Inc Funktionelle und hyperfunktionelle sirna
WO2004064737A2 (fr) 2003-01-17 2004-08-05 Alnylam Pharmaceuticals Compositions therapeutiques
WO2004080406A2 (fr) 2003-03-07 2004-09-23 Alnylam Pharmaceuticals Compositions therapeutiques
EP2666858A1 (fr) 2003-04-17 2013-11-27 Alnylam Pharmaceuticals Inc. Agents iARN modifiés
CA2522349A1 (fr) 2003-04-17 2004-11-04 Alnylam Pharmaceuticals, Inc. Monomeres proteges
TW572579U (en) * 2003-05-12 2004-01-11 Enermax Technology Corp Power supply still capable of dissipating heat after powering off a computer
WO2005007623A2 (fr) 2003-07-03 2005-01-27 The Trustees Of The University Of Pennsylvania Inhibition de l'expression d'une syk kinase
WO2005076999A2 (fr) * 2004-02-05 2005-08-25 Intradigm Corporation Procedes et compostions de combinaison de traitements arni
AU2005230684B2 (en) * 2004-04-05 2011-10-06 Alnylam Pharmaceuticals, Inc. Process and reagents for oligonucleotide synthesis and purification
US7297786B2 (en) 2004-07-09 2007-11-20 University Of Iowa Research Foundation RNA interference in respiratory epitheial cells
US7592322B2 (en) 2004-10-22 2009-09-22 Alnylam Pharmaceuticals, Inc. RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
WO2006121464A2 (fr) * 2004-11-05 2006-11-16 Intradigm Corporation Compositions pour le traitement d'infections virales respiratoires et utilisations associees
NZ556097A (en) * 2005-01-07 2009-12-24 Alnylam Pharmaceuticals Inc Rnai modulation of RSV and therapeutic uses thereof
CA2603730A1 (fr) * 2005-03-31 2006-10-05 Calando Pharmaceuticals, Inc. Inhibiteurs de la sous-unite 2 de la ribonucleotide reductase et utilisations associees
US20070213293A1 (en) * 2005-04-08 2007-09-13 Nastech Pharmaceutical Company Inc. Rnai therapeutic for respiratory virus infection
EP2008274B1 (fr) * 2006-03-31 2015-05-27 Alnylam Pharmaceuticals Inc. Compositions et methodes destinees a inhiber l'expression du gene eg5
US8598333B2 (en) * 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
WO2009055445A2 (fr) 2007-10-22 2009-04-30 Sirna Therapeutics, Inc. Inhibition induite par l'interférence arn de l'expression du virus syncytial respiratoire (vsr), au moyen d'un acide nucléique interférant court (sina)
US20090238772A1 (en) * 2007-12-13 2009-09-24 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of rsv infection
EP2350277A1 (fr) 2008-10-23 2011-08-03 Alnylam Pharmaceuticals, Inc. Procédés et compositions pour la prévention ou le traitement d'une infection par le rsv à l'aide de molécules d'arn en duplex modifiées

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995023225A2 (fr) * 1994-02-23 1995-08-31 Ribozyme Pharmaceuticals, Inc. Procede et reactif inhibiteur de l'expression de genes concernant une affection
WO2004090108A2 (fr) * 2003-04-03 2004-10-21 Alnylam Pharmaceuticals Conjugues d'arni

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHANG WEIDONG ET AL: "Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene", NATURE MEDICINE, vol. 11, no. 1, January 2005 (2005-01-01), pages 56 - 62, XP002410946, ISSN: 1078-8956, DOI: 10.1038/NM1174 *

Also Published As

Publication number Publication date
US8158773B2 (en) 2012-04-17
US8263572B2 (en) 2012-09-11
US20090233984A1 (en) 2009-09-17
KR20070110019A (ko) 2007-11-15
WO2006074346A2 (fr) 2006-07-13
JP2014156491A (ja) 2014-08-28
NZ556097A (en) 2009-12-24
US20060258608A1 (en) 2006-11-16
CN101119734A (zh) 2008-02-06
EP2487243A2 (fr) 2012-08-15
WO2006074346A3 (fr) 2007-07-05
IL217332A0 (en) 2012-02-29
US20150011612A1 (en) 2015-01-08
JP2008526876A (ja) 2008-07-24
EP1833490A2 (fr) 2007-09-19
AU2006203934A1 (en) 2006-07-13
US20130005791A1 (en) 2013-01-03
EA200701450A1 (ru) 2008-02-28
IL184162A0 (en) 2007-10-31
US8859750B2 (en) 2014-10-14
EP2230304B1 (fr) 2012-03-28
EA200900681A1 (ru) 2009-12-30
EP2230304A1 (fr) 2010-09-22
CN101119734B (zh) 2012-05-09
JP2012006980A (ja) 2012-01-12
EP2487243A3 (fr) 2013-08-28
ES2385811T3 (es) 2012-08-01
US7507809B2 (en) 2009-03-24
ATE551421T1 (de) 2012-04-15
AU2006203934B2 (en) 2010-09-09
JP5814728B2 (ja) 2015-11-17
EP1833490A4 (fr) 2010-09-15
CA2594334A1 (fr) 2006-07-13
JP5081630B2 (ja) 2012-11-28
EP2628799A2 (fr) 2013-08-21
EA012573B1 (ru) 2009-10-30
AU2010224450B2 (en) 2014-04-10
US7981869B2 (en) 2011-07-19
KR101169668B1 (ko) 2012-08-07
EA201201356A1 (ru) 2013-07-30
DK2230304T3 (da) 2012-07-16
CN102600480B (zh) 2015-07-22
CN102600480A (zh) 2012-07-25
US7517865B2 (en) 2009-04-14
AU2010224450A1 (en) 2010-10-21
US20130030037A1 (en) 2013-01-31
IL217332A (en) 2013-07-31
US20060166921A1 (en) 2006-07-27
EA017847B1 (ru) 2013-03-29
US20110313023A1 (en) 2011-12-22
US20090240043A1 (en) 2009-09-24
IL184162A (en) 2013-07-31

Similar Documents

Publication Publication Date Title
EP2628799A3 (fr) Modulation ARNi de RSV et utilisations thérapeutiques associées
EP2123759A3 (fr) ARN stabilisés en tant que contrôles de la transfection et réactifs silencieux
RU2010139908A (ru) Модуляция rsv, piv и других респираторных вирусов с помощью rnai и ее применение
WO2004033620A3 (fr) Procedes et compositions permettant l'utilisation therapeutique de l'interference arn
WO2007134161A3 (fr) Compositions et procédés d'inhibition de l'expression du gène pcsk9
WO2004029212A3 (fr) Silencage genique in vivo effectue par un siarn stable et chimiquement modifie
WO2008116860A3 (fr) Compositions d'arn double brin et procédés de traitement d'infections par le virus du papillome humain (hpv)
JP2008526876A5 (fr)
WO2007051045A3 (fr) Compositions et methodes destinees a inhiber l'expression du gene huntingtine
WO2007137156A3 (fr) Modulation d'aha par l'arn et utilisateurs thérapeutiques de celle-ci
WO2008036638A3 (fr) MODULATION PAR L'ARNi DE GÈNE SCAP ET UTILISATIONS THÉRAPEUTIQUES
WO2007115168A8 (fr) Compositions et méthodes destinées à inhiber l'expression du gène eg5
WO2009102427A3 (fr) Polynucléotides d'arni modifiés et leurs utilisations
WO2008036933A3 (fr) Compositions et procédés servant à inhiber l'expression du gène hamp
WO2007056326A3 (fr) Compositions et methodes pour inhiber l'expression du gene nav1.8
WO2004028471A3 (fr) Therapeutique antigrippale
WO2003008573A3 (fr) Extinction d'expression genique
WO2007127919A3 (fr) Compositions et procédés d'inhibition de l'expression d'un gène du virus jc
WO2007137220A3 (fr) Compositions et méthodes inhibant l'expression du gène ikk-b
WO2004071430A3 (fr) Ciblage iarn de virus
HK1159988A1 (en) Compositions and methods for inhibiting expression of factor v leiden mutant gene
WO2004089983A3 (fr) Sras
WO2007111998A3 (fr) Compositions d'arndb et procedes de traitement d'une infection par l'hpv
WO2005042719A3 (fr) Methodes permettant de traiter et de prevenir lesion ischemique au retour de la perfusion a l'aide d'agents interferant avec l'adn
RU2007115097A (ru) Модуляция rsv, piv и других респираторных вирусов с помощью rnai и ее применение

Legal Events

Date Code Title Description
PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130218

AC Divisional application: reference to earlier application

Ref document number: 2487243

Country of ref document: EP

Kind code of ref document: P

Ref document number: 1833490

Country of ref document: EP

Kind code of ref document: P

Ref document number: 2230304

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/113 20100101AFI20130719BHEP

Ipc: A61K 31/713 20060101ALI20130719BHEP

Ipc: A61P 31/00 20060101ALN20130719BHEP

17Q First examination report despatched

Effective date: 20160222

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160705